Hotgen: The Phase I clinical research progress of the innovative drug SGC001, in which the company holds shares, is proceeding smoothly

Hotgen announced that recently, the company received a report from its affiliated company, Beijing ShunJing Biomedical Technology Co., Ltd., regarding the progress of the Phase I clinical study of the innovative drug SGC001 injection developed independently. The project has completed the Phase Ia clinical study in healthy volunteers, and the Phase Ib clinical study in patients with anterior ST-segment elevation myocardial infarction is progressing smoothly, having completed clinical observations for all subjects, and the database has been locked and unblinded. SGC001 injection has shown good safety and tolerability in both healthy volunteers and patients with anterior ST-segment elevation myocardial infarction, with no grade 3 or higher adverse events occurring in the low, medium, and high dose groups during the Phase Ib clinical study, and no serious adverse events reported. Preliminary analysis indicates that the initial efficacy results of SGC001 at different doses in patients with anterior ST-segment elevation myocardial infarction are generally consistent with expectations, and statistical analysis and summary of the research report are currently underway